Deanne Miller - Prima Biomed Insider

Prima Biomed Ltd -- USA Stock  

USD 0.01  0.00  0.00%

General Counsel, Company Secretary

Ms. Deanne Miller, LLB, serves as Chief Operating Officer, General Counsel, Company Secretary of Prima BioMed Ltd. Ms Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.
Age: 38  Executive Since 2016      
61 2 8315 7003  http://www.primabiomed.com.au
Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Management Efficiency

The company has return on total asset (ROA) of (15.25) % which means that it has lost $15.25 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (30.29) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.54 M in total debt with debt to equity ratio (D/E) of 21.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Prima Biomed Ltd has Current Ratio of 5.93 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Prima Biomed is traded on OTC Market in USA.Prima Biomed Ltd (PRRUF) is traded on OTC Market in USA. It is located in 95 Pitt Street and employs 31 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Prima Biomed Ltd to your portfolio

Top Management

Prima Biomed Leadership Team
Pete Meyers, Director, MBA
Russell Howard, Director, Ph.D
Larisa Chisholm, Executive
Tom Bloomfield, Executive
YueLing Wong, Chairman
Frederic Triebel, Executive
Deanne Miller, Executive
Sharron Gargosky, Executive, Ph.D
Grant Chamberlain, Director
Lucy Turnbull, Chairman
Marc Voigt, CEO
Matthew Gregorowski, Executive

Stock Performance

Prima Biomed Performance Indicators